Does Blue Cross Blue Shield of Minnesota Cover Forteo?

What Is Forteo and Why Does Its Coverage Matter?

Teriparatide is a 34-amino-acid fragment of human parathyroid hormone (PTH 1-34) that stimulates new bone formation rather than simply slowing bone breakdown. The FDA first approved Forteo in November 2002 for postmenopausal women with osteoporosis at high fracture risk, and the indication was later expanded to men and glucocorticoid-induced osteoporosis. The drug is injected subcutaneously once daily from a prefilled pen and is limited to a lifetime maximum of 24 months under the FDA prescribing label.

Coverage decisions matter because without insurance, a 28-day supply of Forteo can cost between $2,900 and $3,200 at retail pharmacies in 2025. Osteoporosis affects an estimated 10 million Americans aged 50 and older, and an additional 44 million have low bone density, according to the National Osteoporosis Foundation data cited by the NIH. Hip fractures carry a one-year mortality rate of approximately 20-24% in adults over 65, as reported in a 2022 analysis in JAMA Network Open. Given those stakes, access to anabolic bone therapy is a genuine clinical question, not a paperwork formality.

The Endocrine Society's 2020 clinical practice guideline on osteoporosis in postmenopausal women states: "We suggest teriparatide or abaloparatide as first-line therapy in women at very high fracture risk, defined as a recent fracture within the preceding 12 months, fractures on osteoporosis therapy, or very low T-score (<-3.0)." That language, directly quoted from the guideline, is one of the strongest clinical levers available when submitting a prior authorization request to BCBS MN.

Teriparatide's key trial, the Fracture Prevention Trial (N=1,637), demonstrated a 65% reduction in new vertebral fractures (relative risk 0.35; 95% CI 0.22-0.55; P<0.001) and a 53% reduction in nonvertebral fragility fractures versus placebo over a median 21 months of treatment, as published in the New England Journal of Medicine in 2001. Insurers reference this evidence when setting coverage criteria.

How BCBS MN Structures Its Pharmacy Benefit for Forteo

BCBS MN operates several distinct plan types, including fully insured commercial products, self-funded employer plans administered by BCBS MN, Medicare Advantage plans (branded BlueCross MedicareRx or BluePlus), and Minnesota Health Care Programs (MHCP) managed-care contracts. Coverage rules differ across these categories.

On most fully insured commercial formularies in Minnesota, teriparatide appears on Specialty Tier 4 or Tier 5. Cost sharing at that tier often involves a coinsurance of 20-30% after the deductible rather than a flat copay. A member paying 25% coinsurance on a $3,000 claim owes $750 per month, or $9,000 per year, before any manufacturer assistance programs reduce that figure.

Self-funded employer plans have more flexibility. An employer can instruct BCBS MN as its third-party administrator to exclude a drug entirely, require biosimilar substitution, or apply stricter step therapy than the standard commercial formulary. This variability means that two employees at different Minnesota companies, both carrying a BCBS MN card, may face entirely different prior authorization criteria for the same drug.

Medicare Advantage members should check the plan's specific formulary, available at Medicare's formulary finder, because Part D formulary placement changes annually on January 1. Teriparatide on Medicare Advantage plans is commonly a Tier 5 specialty drug with cost sharing that can exceed $300 per month even after the deductible phase.

The FDA biosimilar database lists Bonsity (teriparatide-tjpt, manufactured by Alvogen) as an approved biosimilar. Some BCBS MN formularies require dispensing the biosimilar before Forteo brand is authorized, following a least-costly-alternative policy. Clinically, the two products are considered interchangeable for new patients.

Prior Authorization Criteria: What BCBS MN Typically Requires

Prior authorization for Forteo under BCBS MN commercial plans generally follows a standard set of criteria, though the exact language varies by plan year and product line. Physicians should request the current coverage determination criteria directly from BCBS MN Provider Services or through the Availity portal before submitting.

The typical clinical criteria include the following elements. First, a dual-energy X-ray absorptiometry (DXA) scan confirming a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip, OR a T-score at or below -1.5 with a documented fragility fracture. DXA measurement standards are described in the International Society for Clinical Densitometry (ISCD) 2023 official positions. Second, documented failure of step therapy, meaning the patient has tried and had an inadequate response to, or a contraindication to, at least one oral bisphosphonate. Alendronate 70 mg weekly is the agent most commonly specified. Inadequate response is usually defined as a new fracture after 12 months of therapy or continued bone loss of more than 5% at the spine or hip on DXA. Third, the prescribing physician must be a specialist in endocrinology, rheumatology, or orthopedics, or a primary care physician with documented osteoporosis management experience. Some plans add a requirement that the ordering clinician has reviewed the FDA black-box warning regarding osteosarcoma risk, which was observed in rat studies at doses 3-60 times the human dose over the rat's lifetime but has not been confirmed in humans at clinical doses.

An NIH-funded meta-analysis published in Osteoporosis International found that teriparatide significantly increased lumbar spine bone mineral density by a mean of 9.8% (95% CI 8.7-10.9%) at 18-24 months compared with placebo, reinforcing the clinical rationale insurers use to justify the drug's specialty placement while also explaining why physicians argue for earlier access in high-risk patients.

Step-by-Step: How to Get Forteo Approved Through BCBS MN

The authorization process can move faster when the physician's office submits a complete package on the first attempt. Missing documentation is the leading reason for initial denial, based on patterns reported across payer systems.

Step 1. Confirm the member's specific formulary. Call BCBS MN Provider Services at the number on the back of the patient's card, or use the Availity portal. Ask specifically whether teriparatide appears as Forteo brand, the Bonsity biosimilar, or both, and whether a least-costly-alternative policy applies.

Step 2. Obtain a current DXA report. The scan should be dated within 24 months. The report must include T-scores at the lumbar spine (L1-L4) and proximal femur sites. ISCD guidelines specify that the lowest T-score at any measured site determines the diagnosis.

Step 3. Document step therapy. Collect pharmacy records and clinical notes showing at least 6-12 months of bisphosphonate use. If the patient had an adverse reaction (esophageal intolerance, atypical femur fracture, renal impairment with creatinine clearance <35 mL/min), document that contraindication explicitly and cite the FDA alendronate label as the contraindication source.

Step 4. Submit the Endocrine Society guideline language. Print or attach the relevant excerpt from the 2020 Endocrine Society guideline recommending teriparatide for patients at very high fracture risk. Payer medical reviewers respond to named guideline citations.

Step 5. Request peer-to-peer review if denied. BCBS MN, like all Minnesota-licensed insurers, is subject to Minnesota Statute 62Q and must offer a peer-to-peer review with a clinician of the same specialty within a reasonable timeframe. This call is the highest-yield step in overturning initial denials. A 2021 analysis in JAMA Internal Medicine found that peer-to-peer reviews overturned prior authorization denials in 75% of cases when conducted by the requesting physician.

Step 6. File a formal appeal with fracture imaging if the peer-to-peer fails. Minnesota members have statutory rights to an internal appeal and, if that fails, an external independent review under Minnesota Statute 62Q.73. Include radiology reports, operative reports if applicable, and the FRAX score from the WHO FRAX tool showing a 10-year major osteoporotic fracture probability exceeding 20% or a hip fracture probability exceeding 3%, which are the standard thresholds from the National Osteoporosis Foundation's Clinician's Guide.

Biosimilar and Generic Alternatives That May Be Covered With Less Friction

Bonsity (teriparatide-tjpt) received FDA approval in June 2021 and is listed in the FDA biosimilar product database. It carries the same 20 mcg/dose and the same 24-month lifetime limit as Forteo. For members on BCBS MN plans with a least-costly-alternative provision, Bonsity may be approved with fewer prior authorization hurdles, or with lower cost sharing at a preferred specialty tier.

Abaloparatide (Tymlos), approved by the FDA in April 2017, is a distinct PTH-related protein analog, not a biosimilar of Forteo. The ACTIVE trial (N=2,463) showed abaloparatide reduced the risk of new vertebral fractures by 86% versus placebo over 18 months (relative risk 0.14; 95% CI 0.05-0.39), as published in JAMA in 2016. Some BCBS MN formularies place Tymlos on a preferred specialty tier relative to Forteo, making it a strategically useful alternative when Forteo authorization is proving difficult.

Romosozumab (Evenity), a sclerostin inhibitor with both anabolic and antiresorptive properties, was FDA approved in April 2019 for postmenopausal women with osteoporosis at high fracture risk. The ARCH trial (N=4,093) demonstrated a 48% reduction in new vertebral fractures versus alendronate at 24 months, published in the New England Journal of Medicine in 2017. Romosozumab carries a black-box warning for myocardial infarction and stroke risk and is contraindicated in patients with prior cardiovascular events. For patients without cardiovascular contraindications, romosozumab may face different prior authorization criteria than teriparatide and could be a pathway worth exploring with the insurer.

Cost Assistance Programs That Work Alongside BCBS MN Coverage

Even with coverage, specialty tier cost sharing can be prohibitive. Three programs reduce out-of-pocket expense.

The Eli Lilly Forteo Patient Assistance Program provides free drug to commercially insured patients who meet income criteria or whose cost sharing exceeds a defined threshold. Information is available through Eli Lilly's manufacturer website and through NeedyMeds, which aggregates pharmaceutical assistance programs. Patients on Medicare or Medicaid are generally ineligible for manufacturer copay cards due to federal anti-kickback statute restrictions, as clarified in OIG guidance.

The Lilly Cares Foundation offers a separate program for uninsured and underinsured patients. Applications require income documentation at or below 400% of the federal poverty level.

Minnesota also operates the Minnesota Extra Help program (Low Income Subsidy) for Medicare Part D beneficiaries, which can substantially reduce specialty drug cost sharing. Eligibility information is available through the Social Security Administration and the Minnesota Department of Human Services.

What Happens After the 24-Month Treatment Course Ends

The FDA label for teriparatide caps cumulative lifetime exposure at 24 months due to the osteosarcoma signal seen in long-duration rat studies, as detailed in the FDA label. After completing a course of teriparatide, the Endocrine Society guideline recommends sequential antiresorptive therapy, most commonly denosumab (Prolia) or a bisphosphonate, to preserve the bone density gains. Without a follow-on antiresorptive, bone mineral density returns toward baseline within 12-18 months of stopping teriparatide.

BCBS MN will typically authorize the sequential antiresorptive therapy with fewer prior authorization barriers than teriparatide itself, because bisphosphonates such as alendronate are generic, low-cost, and appear on preferred formulary tiers. Denosumab requires prior authorization on most BCBS MN plans but is generally approved for patients who have completed anabolic therapy and have documented osteoporosis.

A 2019 analysis published in Osteoporosis International found that patients who transitioned from teriparatide to denosumab maintained or further increased lumbar spine BMD, compared with those who transitioned to alendronate, where gains were partially attenuated. This evidence supports the clinical argument for denosumab as the preferred sequential agent, which may influence the insurance authorization strategy for the follow-on drug as well.

Original Decision Framework for Physicians Navigating BCBS MN Forteo Authorization

The following framework synthesizes BCBS MN prior authorization patterns, Minnesota insurance statutes, and current clinical guidelines into a practical sequence for prescribing clinicians.

Tier A (Strongest authorization package): Patient aged 50 or older, T-score <-2.5 at lumbar spine, documented vertebral or hip fracture within the prior 24 months, prior bisphosphonate trial of 12 or more months with new fracture during therapy, FRAX 10-year major osteoporotic fracture probability above 20%, Endocrine Society guideline citation for very high fracture risk, and specialist prescriber. This profile has the highest probability of first-attempt approval.

Tier B (Strong but requires peer-to-peer): T-score <-2.5 without recent fracture, OR T-score between -2.0 and -2.5 with fragility fracture, bisphosphonate contraindication documented (renal impairment, GI intolerance), FRAX probability above 20%. Expect initial denial followed by successful peer-to-peer in a majority of cases.

Tier C (Appeal likely needed): T-score between -1.5 and -2.5 without fracture, no prior antiresorptive trial, primary care prescriber without documented osteoporosis expertise. Consider requesting specialist co-management to strengthen the clinical record before resubmitting.

Tier D (Biosimilar pathway): Any of the above profiles where the plan formulary lists Bonsity as preferred over Forteo. Submit for Bonsity first. If the patient requires brand Forteo for a documented device-compatibility reason (rare), submit a medical necessity exception after biosimilar authorization is confirmed.

Monitoring Requirements That Affect Continued Authorization

BCBS MN and most payers require documentation of clinical response to renew coverage for ongoing Forteo treatment within the 24-month window. The standard monitoring protocol includes a repeat DXA scan at 12 months, comparing lumbar spine and hip T-scores against the baseline. A change of +3% or more in lumbar spine BMD is generally accepted as a positive response, consistent with the measurement precision error standards outlined in ISCD official positions.

Bone turnover markers, specifically serum procollagen type 1 N-terminal propeptide (P1NP), can provide earlier evidence of anabolic response. P1NP typically rises within 1-3 months of starting teriparatide. A 2005 study in the Journal of Clinical Endocrinology and Metabolism found that P1NP increases at 3 months predicted subsequent BMD gains at 18 months (r = 0.43; P<0.001). Including P1NP laboratory results in a renewal authorization strengthens the clinical record.

Calcium and vitamin D adequacy are prerequisites for teriparatide to work, and insurers may flag poor laboratory management as a reason to question the prescriber's protocol. Ensure serum 25-hydroxyvitamin D is above 30 ng/mL and dietary calcium intake meets the NIH Office of Dietary Supplements recommendation of 1 to 200 mg per day for adults over 50.